← Azimuth Daily
Capturing data…
Capturing data…
SUN, 25 OCT · 77 ITEMS
NEJM, Sydney Morning Herald, The Age + 1 more · Science & Medicine
4 outletsis a being tested as a targeted therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose cancer has progressed after prior chemotherapy. The primary results from the RASolute 303 trial, published in the New England Journal of Medicine, showed that daraxonrasib reduced the risk of death by 60% in patients with RAS G12 mutations and improved overall survival compared to chemotherapy. This led to FDA approval in August 2026, making it the first targeted therapy approved for this aggressive cancer. The NEJM eTOC item highlights these practice-changing results.
The claim is highly authoritative: it refers to primary results from a randomized trial published in the New England Journal of Medicine (NEJMoa2605555) and supported by an FDA approval announcement. The reporting sits directly on the peer-reviewed paper and official regulatory action, consistent with the primary-source provenance tier.
The underlying trial results and FDA approval were published in 2026, making this genuinely new material with no recirculation.
We covered acquired resistance to daraxonrasib and rational combination strategies in pancreatic cancer on August 12, 2026, which builds on the efficacy data highlighted here.